Agilvax
Albuquerque
About Agilvax
Agilvax is a private company that discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. The company identifies and selects lead vaccine candidates through its proprietary affinity optimizes those by in vitro and in vivo testing and develops them through pre-clinical and/or clinical testing until proof of concept is achieved establishing attractive out-licensing opportunities to Pharma or Biotech partners. Collaborations and partnerships are actively pursued within the industry, academia, and the government sector through NIAID.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $10.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2020)
- Website: agilvax.com
- Phone: 5057974531
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/agilvax-45892 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.